Fluorophore-assisted retinal break detection using antibodies to glial fibrillary acidic protein

Investigative Ophthalmology and Visual Science

Volumn 45, Issue 3, 2004, Pages 993-1001

  Jackson, Timothy L ^a   Marshall, John ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BLOCKING ANTIBODY; CY3 GLIAL FIBRILLARY ACIDIC PROTEIN ANTIBODY; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN ANTIBODY; TRYPAN BLUE; UNCLASSIFIED DRUG; CARBOCYANINE; CYANINE DYE 3; DIAGNOSTIC AGENT; FLUORESCENT DYE; MONOCLONAL ANTIBODY;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CATTLE; CELL MEMBRANE; CONTROLLED STUDY; CROSS REACTION; DIODE LASER; EX VIVO STUDY; EXCIMER LASER; FLUORESCENCE; FLUORESCENT ANTIBODY TECHNIQUE; GLIA CELL; HUMAN; HUMAN TISSUE; ILLUMINATION; INTERMEDIATE FILAMENT; INTRAOPERATIVE PERIOD; MEMBRANE; MEMBRANE DAMAGE; MUELLER CELL; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINA DETACHMENT; RETINA INTERNAL LIMITING MEMBRANE; RETINA TEAR; RHEGMATOGENOUS RETINA DETACHMENT; SWINE; VITAL STAIN; VITRECTOMY; AGED; ANIMAL; FLUORESCENCE MICROSCOPY; GLIA; IMMUNOLOGY; METHODOLOGY; PATHOLOGY; PATIENT MONITORING; SPECIES DIFFERENCE; STAINING;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; CARBOCYANINES; CATTLE; FLUORESCENT DYES; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MICROSCOPY, FLUORESCENCE; MONITORING, INTRAOPERATIVE; NEUROGLIA; RABBITS; RETINAL DETACHMENT; RETINAL PERFORATIONS; SPECIES SPECIFICITY; STAINING AND LABELING; SWINE; VITRECTOMY;

EID: 1542427161     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.03-0791     Document Type: Article

References (50)

1. Minihan M, Tanner V, Williamson TH. Primary rhegmatogenous retinal detachment: 20 years of change. Br J Ophthalmol. 2001; 85:546-548.
2. Sullivan PM, Luff AJ, Aylward GW. Results of primary retinal reattachment surgery: a prospective audit. Eye. 1997;11:869-871.
3. Tornambe PE, Hilton GF. Pneumatic retinopexy: a multicenter randomized controlled trial comparing pneumatic retinopexy with scleral buckling (Retinal Detachment Study Group). Ophthalmology. 1989;96:772-783.
4. Sharma T, Challa JK, Ravishankar KV. Scleral buckling for retinal detachment: predictors of anatomic failure. Retina. 1994;14:338-343.
5. Snead MP, Scott JD. Results of primary retinal detachment surgery: a prospective audit. Eye. 1998;12:750.
6. Wong D, McGalliard J. Are we getting better at treating retinal detachment? - technology, referral pattern or primary care? Eye. 1997;11:763-764.
7. Thompson JA, Snead MP, Billington BM, Barrie T, Thompson JR, Sparrow JM. National audit of the outcome of primary surgery for rhegmatogenous retinal detachment. I. Sample and methods. Eye. 2002;16:766-770.
8. Thompson JA, Snead MP, Billington BM, Barrie T, Thompson JR, Sparrow JM. National audit of the outcome of primary surgery for rhegmatogenous retinal detachment. II. Clinical outcomes. Eye. 2002,16:771-777.
9. Han DP, Mohsin NC, Guse CE, Hartz A, Tarkanian CN. Comparison of pneumatic retinopexy and scleral buckling in the management of primary rhegmatogenous retinal detachment. Southern Wisconsin Pneumatic Retinopexy Study Group. Am J Ophthalmol. 1998; 126:658-668.
10. Cowley M, Conway BP, Campochiaro PA, Kaiser D, Gaskin H. Clinical risk factors for proliferative vitreoretinopathy. Arch Ophthalmol. 1999;107:1147-1151.
11. Bonnet M. Clinical factors predisposing to massive proliferative vitreoretinopathy in rhegmatogenous retinal detachment. Ophthalmologica. 1984;188:148-152.
12. Tani P, Robertson DM, Langworthy R. Rhegmatogenous retinal detachment without macular involvement treated with scleral buckling. Am J Ophthalmol. 1980;90:503-508.
13. Laidlaw DA, Clark B, Grey RH, Markham RH. Results of primary retinal detachment surgery: a prospective audit. Eye. 1998;12:751.
14. Chignell AH, Fison LG, Davies EWG, Hartly RE, Gundry MF. Failure in retinal detachment surgery. Br J Ophthalmol. 1973;57:525-530.
15. Froussard F, Chauvaud D. Anatomic results of buckle surgery for retinal detachments with undetected break (in French). J Fr Ophtalmol. 2001;24:345-347.
16. Machemer R. Experimental retinal detachment in the owl monkey: histology of the retina and pigment epithelium. Am J Ophthalmol. 1968;66:396-410.
17. Erickson PA, Feinstein SC, Lewis GP, Fisher SK. Glial fibrillary acidic protein and its mRNA: ultrastructural detection and determination of changes after CNS injury. J Struct Biol. 1992;108:148-161.
18. Lillie RD. H. J. Conn's Biological Stains. 9th ed. Baltimore: Williams and Wilkins; 1977.
19. Jackson TL, Hillenkamp J, Williamson TH, Clarke KW, Almubarak AI, Marshall J. An experimental model of rhegmatogenous retinal detachment: surgical results and glial cell response. Invest Ophthalmol Vis Sci. 2003;44:4026-4034.
20. Anderson DH, Guérin CJ, Erickson PA, Stern WH, Fisher SK. Morphological recovery in the reattached retina. Invest Ophthalmol Vis Sci. 1986;27:168-183.
21. Anderson DH, Stern WH, Fisher SK, Erickson PA, Borgula GA. Retinal detachment in the cat: the pigment epithelial-photoreceptor interface. Invest Ophthalmol Vis Sci. 1983;24:906-926.
22. Mujumdar RB, Ernst LA, Mujumdar SR, Lewis CJ, Waggoner AS. Cyanine dye labelling reagents: sulfoindocyanine succinimidyl esters. Bioconjugate Chem. 1993;4:105-111.
23. Lincoff H. Should retinal breaks be closed at the time of surgery? In: Brokhurst RJ, Boruchoff SA, Hutchinson BT, Lessell S, eds. Controversy in Ophthalmology. Philadelphia: WB Saunders; 1977: 582-598.
24. Sorsby A. Vital staining of the fundus. Trans Ophthalmol Soc UK. 1939;59:727-730.
25. Black GW. Some aspects of the treatment of simple detachment of the retina, including vital staining of the retina by methylene blue. Trans Ophthalmol Soc UK. 1947;67:313-322.
26. Kutschera E. Vital staining of the detached retina with retinal breaks (in German). Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1969;178:72-87.
27. Melles, GRJ, de Waard, PWT, Pameyer, JH, Beekhuis, WH. Trypan blue capsule staining to visualize the capsulorhexis in cataract surgery. J Cataract Refract Surg. 1999;25:7-9.
28. Kadonosono K, Itoh N, Uchio E, Nakamura S, Ohno S. Staining of internal limiting membrane in macular hole surgery. Arch Ophthalmol. 2000;118:1116-1118.
29. Da Mata AP, Burk SB, Riemann CD, et al. Indocyanine greenassisted peeling of the retinal internal limiting membrane during vitrectomy surgery for macular hole repair. Ophthalmology. 2001; 108:1187-1192.
30. Bignami A, Dahl D. The radial glia of Müller in the rat retina and their response to injury: an immunofluorescence study with antibodies to glial fibrillary (GFA) protein. Exp Eye Res. 1979;28: 63-69.
31. Lewis GP, Matsumoto B, Fisher SK. Changes in the organization and expression of cytoskeletal proteins during retinal degeneration induced by retinal detachment. Invest Ophthalmol Vis Sci. 1995;36:2404-2416.
32. Schnitzer J. Distribution and immunoreactivity of glia in the retina of the rabbit. J Comp Neurol. 1985;240:128-142.
33. Gilbert DS. Axoplasm chemical composition in Myxicola and solubility properties of its structural proteins. J Physiol. 1975;253: 303-319.
34. Gilbert DS. Axoplasm architecture and physical properties as seen in the Myxicola giant axon. J Physiol. 1975;253:257-301.
35. Chin TK, Eagles PAM, Maggs A. The proteolytic digestion of ox neurofilaments with trypsin and alpha-chymotrypsin. Biochem J. 1983;215:239-252.
36. Wais-Steider C, White NS, Gilbert DS, Eagles PA. X-ray diffraction patterns from microtubules and neurofilaments in axoplasm. J Mol Biol. 1987;197:205-218.
37. Eisenfield AJ, Bunt-Milam AH, Sarthy PV. Müller cell expression of glial fibrillary acidic protein after genetic and experimental photoreceptor degeneration in the rat retina. Invest Ophthalmol Vis Sci. 1984;25:1321-1328.
38. Tyler NK, Burns MS. Alterations in glial cell morphology and glial fibrillary acidic protein expression in urethane-induced retinopathy. Invest Ophthalmol Vis Sci. 1991;32:246-256.
39. Yoshida A, Ishiguro S, Tumai M. Expression of glial fibrillary acidic protein in rabbit Müller cells after lensectomy-vitrectomy. Invest Ophthalmol Vis Sci. 1993;34:3154-3160.
40. Humphrey MF, Constable IJ, Chu Y, Wiffen S. A quantitative study of the lateral spread of Müller cell responses to retinal lesions in the rabbit. J Comp Neurol. 1993;334:545-558.
41. Lewis GP, Guérin CJ, Anderson DH, Matsumoto B, Fisher SK. Rapid changes in the expression of glial cell proteins caused by experimental retinal detachment. Am J Ophthalmol. 1994;118:368-376.
42. Laqua H, Machemer R. Glial cell proliferation in retinal detachment (massive periretinal proliferation). Am J Ophthalmol. 1975;80: 602-618.
43. Kroll AJ, Machemer R. Experimental retinal detachment in the owl monkey. III. Electron microscopy of retina and pigment epithelium. Am J Ophthalmol. 1968;66:410-427.
44. Foos RY. Retinal tears and lesser lesions of the peripheral retina in autopsy eyes. Am J Ophthalmol. 1967;64:643-655.
45. Burstein NL, Leopold JH, Bernacchi DB. Trans-scleral iontophoresis of gentamicin. J Ocul Pharmacol. 1985;2:153-164.
46. Ambati J, Gragoudas ES, Miller JW, et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci. 2000;41:1186-1191.
47. Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000;41:1181-1185.
48. Glennie MJ, Johnson PWM. Clinical trials of monoclonal antibodies. Immunol Today. 2000;21:403-410.
49. Kamizaru H, Kimura H, Yasukawa T, Tabata Y, Honda Y, Ogura Y. Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat. Invest Ophthalmol Vis Sci. 2001;42:2664-2672.
50. Cordiero MF, Gay JA, Khaw PT. Human anti-transforming growth factor-2 antibody: a new glaucoma scarring agent. Invest Ophthalmol Vis Sci. 1999;40:2225-2234.